Main Entry Criteria. Adults with partial seizures

Comparator. Valproate

Number of Patients. 156

Primary Outcome Variable. Proportion of patients who met the escape criteria

Results. Fewer patients receiving lamotrigine 500 mg/day (42%) met the escape criteria compared to those receiving valproate 1,000 mg/day (69%).

Main Entry Criteria. New-onset epilepsy

Comparator. Gabapentin

Number of Patients. 309

Primary Outcome Variable. Percentage completers

Important Secondary Outcome Variables. Time to first seizure and withdrawal rate for adverse events

Results. There were no differences in completer rate or time to first seizure. Better tolerability was observed in the lamotrigine group.

Main Entry Criteria. New-onset epilepsy

Comparator. Carbamazepine

Number of Patients. 260

Primary Outcome Variable. Seizure frequency and time to first seizure

Important Secondary Outcome Variables. Adverse event rate

Results. No difference in seizure frequency or time to first seizure was observed. Fewer withdrawals were observed with lamotrigine.

Main Entry Criteria. New-onset epilepsy

Comparator. Phenytoin

Number of Patients. 181

Primary Outcome Variable. Time to exit

Important Secondary Outcome Variables. Time to first seizure, seizure-free rate during the final 12 weeks and withdrawal rate for adverse events

Results. There were no differences in time to exit and in secondary measures.

Main Entry Criteria. Newly diagnosed epilepsy

Comparator. Carbamazepine

Number of Patients. 150

Primary Outcome Variable. Completion of study

Important Secondary Outcome Variables. Time to first seizure, seizure-free rate during the final 16 weeks, and withdrawal rate for adverse events

Results. Lamotrigine was associated with fewer withdrawals and greater seizure-free rate in the last 16 weeks. No difference in time to first seizure was observed.

Main Entry Criteria. Newly diagnosed epilepsy

Comparator. Gabapentin, carbamazepine

Number of Patients. 593

Primary Outcome Variable. Retention in trial for 12 months

Important Secondary Outcome Variables. Freedom from seizure at 12 months, time to first seizure, drug toxicity

Results. Lamotrigine and gabapentin were superior to carbamazepine in 12-month retention. Fewer withdrawals were observed with lamotrigine compared to that with gabapentin or carbamazepine. No differences in seizure-free rates were observed.

Main Entry Criteria. Adults with medication-resistant seizures

Comparator. Lamotrigine 300 or 500 mg/day, or placebo

Number of Patients. 216

Primary Outcome Variable; Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine 500 mg/day was superior to placebo; lamotrigine 300 mg/day was not different from placebo.

Main Entry Criteria. Adults with medication-resistant seizures

Comparator. Lamotrigine 400 mg/day or placebo

Number of Patients. 98

Primary Outcome Variable; Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine 400 mg/day was superior to placebo.

Main Entry Criteria. Adults with medication-resistant seizures

Comparator. Lamotrigine 150 or 300 mg/day, or placebo

Number of Patients. 41

Primary Outcome Variable; Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine 150 or 300 mg/day was superior to placebo.

Main Entry Criteria. Children (aged 2 to 16 years) with medication-resistant seizures

Comparator. Lamotrigine 5 or 15 mg/kg/day, placebo

Number of Patients. 199

Primary Outcome Variable; Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine was superior to placebo.

Main Entry Criteria. Medication-resistant generalized epilepsy

Comparator. Lamotrigine 75 or 150 mg/day

Number of Patients. 22

Primary Outcome Variable, Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine was associated with reduction in generalized tonic-clonic and absence seizures.

Main Entry Criteria. Children and adults (aged 3 to 25 years) with medication-resistant Lennox-Gastaut syndrome

Comparator. Lamotrigine 5 or 15 mg/kg/day, placebo

Number of Patients. 169

Primary Outcome Variable; Important Secondary Outcome Variables. Median percentage seizure reduction, 50% responder rate

Results. Lamotrigine was superior to placebo.

Main Entry Criteria. Human immunodeficiency virus (HIV)–associated distal sensory polyneuropathy

Comparator. Lamotrigine, placebo

Number of Patients. 92

Primary Outcome Variable; Important Secondary Outcome Variables. Pain scales

Results. Lamotrigine was superior to placebo.

Main Entry Criteria. HIV-associated distal sensory polyneuropathy

Comparator. Lamotrigine, placebo

Number of Patients. 42

Primary Outcome Variable; Important Secondary Outcome Variables. Pain scales

Results. Lamotrigine was superior to placebo.

Main Entry Criteria. Painful diabetic neuropathy

Comparator. Lamotrigine, placebo

Number of Patients. 59

Primary Outcome Variable; Important Secondary Outcome Variables. Pain scales

Results. Lamotrigine was superior to placebo.